Document is current
Any future updates will be listed below
-
Authors
Binder, Jessica https://orcid.org/0000-0003-2091-3950
Ursu, Oleg https://orcid.org/0000-0003-0596-8339
Bologa, Cristian https://orcid.org/0000-0003-2232-4244
Jiang, Shanya https://orcid.org/0000-0001-6564-0859
Maphis, Nicole https://orcid.org/0000-0003-3833-1027
Dadras, Somayeh
Chisholm, Devon
Weick, Jason https://orcid.org/0000-0003-3135-9860
Myers, Orrin
Kumar, Praveen https://orcid.org/0000-0002-4981-9020
Yang, Jeremy J. https://orcid.org/0000-0002-1476-6192
Bhaskar, Kiran https://orcid.org/0000-0001-6064-8106
Oprea, Tudor I. https://orcid.org/0000-0002-6195-6976
- License Information
-
More Information
Article History
Received: 6 November 2020
Accepted: 21 January 2022
First Online: 11 February 2022
Competing interests
: T.I.O. has received honoraria or consulted for Abbott, AstraZeneca, Chiron, Genentech, Infinity Pharmaceuticals, Merz Pharmaceuticals, Merck Darmstadt, Mitsubishi Tanabe, Novartis, Ono Pharmaceuticals, Pfizer, Roche, Roivant Discovery, Sanofi, and Wyeth. He is on the Scientific Advisory Board of ChemDiv Inc. and InSilico Medicine. The remaining authors declare no competing interests.
